ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > FGF-23

FGF-23

概要

Name:Fibroblast growth factor 23
Target Synonym:HFTC2,Tumor-Derived Hypophosphatemia Inducing Factor,UNQ3027/PRO9828,Tumor-derived hypophosphatemia-inducing factor,HYPF,FGF23,Fibroblast Growth Factor 23,Phosphatonin,FGF-23,HPDR2,PHPTC,ADHR,FGFN
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:0
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
FG3-H52H3 Human Human FGF-23 (R179Q) Protein, His Tag
FG3-H52H3-structure
FG3-H52H3-sds
ACRO Quality

Synonym Name

FGF23,HYPF,FGF-23,ADHR,HPDR2

Background

Fibroblast growth factor 23 (FGF23) is is an endocrine member of the family of FGFs and mainly produced in the bone and, upon secretion, forms a complex with a FGF receptor and coreceptor αKlotho. FGF23 can exert several endocrine functions, such as acting as a hormone on the kidney, stimulating phosphate excretion and suppressing formation of 1,25(OH)2D3, active vitamin D. Moreover, it has paracrine activities on several cell types, including neutrophils and hepatocytes. FGF23 and phosphate have been revealed to be factors relevant in cancer. FGF23 is particularly significant for those forms of cancer primarily affecting bone (e.g., multiple myeloma) or characterized by bone metastasis.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Burosumab KRN-23; UX-023 Approved Kyowa Hakko Kirin Co Ltd Crysvita EU Hypophosphatemia, Familial Kyowa Kirin Holdings Bv 2018-02-19 Hypophosphatemia; Fibrous Dysplasia of Bone; Hypophosphatemia, Familial; Genetic Diseases, X-Linked; Osteomalacia; Nevus, Sebaceous of Jadassohn; Familial Hypophosphatemic Rickets Details

This web search service is supported by Google Inc.

totopphone